malignancy managed with RACS in a community hospital. Methods: comparative study of the first 57patients treated with RACS for malignant tumors done from 6/17 to 7/19 in a community hospital. The data was then compared to the published literature. Two
Search Results
Adrian Legaspi, Vanitha Vasudevan, Amit Sastry, Jeronimo Garcialopez de Llano, and Marice Ruiz-Conejo
Ravi B. Parikh, Ramy Sedhom, William J. Ferrell, Katherine Villarin, Kara Berwanger, Bethann Scarborough, Randall Oyer, Pallavi Kumar, Niharika Ganta, Shanthi Sivendran, Jinbo Chen, Kevin G. Volpp, and Justin E. Bekelman
-based criteria to clinicians on (1) PC referrals and completed visits, and (2) quality of life. Methods: This 2-arm pragmatic randomized trial, conducted in a large, rural community oncology practice, randomizes 4 clinician-pods, consisting of approximately 250
Gabriela Abigail Villanueva
marginalized groups. Our objective is to provide quality palliative care to oncology Hispanic patients along the Mexico-US border by using community health workers (promotoras) to deliver a comprehensive and culturally sensitive educational intervention. We
Rie Tamagawa, Shannon Groff, Jennifer Anderson, Sarah Champ, Andrea Deiure, Jennifer Looyis, Peter Faris, and Linda Watson
differed. In the smaller regional and community sites, cancer patient navigators (CPNs) were available for complex distress management. In the larger tertiary cancer centers where the CPN role is not part of the care model, psychologists and social workers
Margaret A. O'Grady, Elena Gitelson, Ramona F. Swaby, Lori J. Goldstein, Elaine Sein, Patricia Keeley, Bonnie Miller, Tianyu Li, Alan Weinstein, and Steven J. Cohen
Fox Chase Cancer Center Partners (FCCCP) is a community hospital/academic partnership consisting of 25 hospitals in the Delaware Valley. Originally created in 1986, FCCCP promotes quality community cancer care through education, quality assurance, and access to clinical trial research. An important aspect of quality assurance is a yearly medical oncology audit that benchmarks quality indicators and guidelines and provides a roadmap for quality improvement initiatives in the community oncology clinical office setting. Each year, the FCCCP team and the Partner Medical Oncologists build disease site- and stage-specific indicators based on National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Concordance with multiple indicators is assessed on 20 charts from each community practice. A report for each FCCCP medical oncology practice summarizes documentation, screening recommendations, new drug use, and research trends in a particular disease site. Descriptive statistics reflect indicators met, number of new cases seen per year, number of disease site cases from tumor registry information, and clinical trial accrual total. Education and documentation tools are provided to physicians and oncology office nursing staff. The FCCCP Clinical Operations Team, consisting of medical oncologists and oncology-certified nurses, has conducted quality audits in medical oncology offices for 7 years using NCCN-derived indicators. Successful audits comprising gastric, colorectal, and breast cancer have been the focus of recent evaluations. For the 2005 stage II/III breast cancer evaluation, mean compliance per parameter was 88%, with 15 of 16 practices achieving mean compliance greater than 80%. A large-scale quality assurance audit in a community cancer partner network is feasible. Recent evaluation of localized breast cancer shows high compliance with guidelines and identifies areas for focused education. Partnership between academic and community oncologists produces a quality review process that is broadly applicable and adaptable to changing medical knowledge.
Bianca Lewis, Caitlin R. Meeker, Elizabeth Handorf, Kelly Filchner, Rino Seedor, Jennifer S. Winn, Lori J. Goldstein, and Efrat Dotan
analysis, we sought to describe the psychosocial profile of older community patients with MBC, and investigate the correlation between psychosocial factors and presence of other GA abnormalities. Methods: This study included hands-on experience
Howland E. Crosswell, Kaitlin N. Bomar, Nicole Vickery, Kristina Stoeppler-Biege, Terra D. Spann, and Robert D. Siegel
approximately 80% of the nearly 70,000 AYA patients diagnosed annually in the United States are seen and/or cared for in the community, understanding and implementing AYA care delivery in nonacademic settings is important. Recent updates to the NCCN Clinical
Shivan J. Mehta, Sanjay Palat, Catherine Reitz, Evelyn Okorie, Caitlin McDonald, Pamela A. Shaw, Karen Glanz, and David A Asch
Background : Effective prevention and screening exists for colorectal cancer (CRC) but is underutilized, particularly in community health settings. Colonoscopy and fecal immunochemical testing (FIT) are both considered top-tier tests according
Alison Roos, Lucio Gordan, Michael Diaz, Anjan Patel, Matthew Fink, David Wenk, John Jiang, Janice Tam, Pratheesh Sathyan, and Phil Febbo
tissue biopsy-based biomarker testing and reflex testing dynamics to understand the current NSCLC biomarker testing scenario in a large US community practice. Methods: Patients with advanced NSCLC (n=250) who received care in a large US community
Dewilka Simons, Yolaine Jeune-Smith, Bruce Feinberg, Stephanie Fortier, and Ajeet Gajra
surveyed community hematologists/oncologists (cH/O) on their perceptions of the OlympiA trial data and the potential impact on their BRCA 1/2 testing habits in patients with early-stage BC. Methods : Between June and October 2021, practicing U.S. cH/O were
